Engineered immune cells take on Hard-to-Treat myeloma

NCT ID NCT04795882

Recruiting now Disease control Sponsor: University College, London Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests two types of engineered immune cells (CAR T cells) in 27 people with multiple myeloma that has come back or not responded to at least three prior treatments. One type targets a protein called BCMA on myeloma cells, and the other targets both BCMA and CD19. The main goals are to see if the cells can be made safely and to check for serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BCMA CAR T cells and BCMA/CD19 CAR T cells
What this could lead to: If successful, this could lead to a new treatment option for patients with multiple myeloma that has not responded to other therapies.
What could go wrong: This is an early Phase 1 trial with only 27 participants, so safety and effectiveness are not yet proven. There are risks of severe side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

University College London Hospital
RECRUITING

London, County (Optional), United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.